Log in

Relevant bibliographies by topics / Sofosbuvir And Velpatasvir / Journal articles

To see the other types of publications on this topic, follow the link: Sofosbuvir And Velpatasvir.

Journal articles on the topic 'Sofosbuvir And Velpatasvir'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sofosbuvir And Velpatasvir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Heo, Jeong, Yoon Jun Kim, Sung Wook Lee, et al. "Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study." Korean Journal of Internal Medicine 38, no. 4 (2023): 504–13. http://dx.doi.org/10.3904/kjim.2022.252.

Full text

Abstract:

Background/Aims: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced

APA, Harvard, Vancouver, ISO, and other styles

2

Chahine, Elias B., Allana J. Sucher, and Brian A. Hemstreet. "Sofosbuvir/Velpatasvir." Annals of Pharmacotherapy 51, no. 1 (2016): 44–53. http://dx.doi.org/10.1177/1060028016668897.

Full text

Abstract:

Objectives: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection. Data Sources: A literature search through PubMed was conducted (June 2008 to August 2016) using the terms GS-5816, velpatasvir, and sofosbuvir. References from retrieved articles and the prescribing information were reviewed for any additional material. Study Selection/Data Extraction: The literature search was limited to human studies published in English. Phase I, II, and III studies of sofosbuvir/velpatasvir for HCV were identified. Data

APA, Harvard, Vancouver, ISO, and other styles

3

Dr., Rajeswar dutt* Thandu venkateshwarlu Santhosh illendula V.Shirisha. "RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR IN COMBINED DOSAGE FORM." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES o6, no. 07 (2019): 13890–903. https://doi.org/10.5281/zenodo.3270795.

Full text

Abstract:

<em>A simple, accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir and Velpatasvir in tablet dosage form. Chromatogram was run through Denali 150 x 4.6 mm, 5</em><em>m</em><em>. Mobile phase containing Buffer 0.01NKH<sub>2</sub>PO<sub>4</sub> (4.8 pH) : Acetonitrile taken in the ratio 65:35 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was 0.01N KH<sub>2</sub>PO<sub>4</sub> (4.8PH) buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 220.0 nm. Retention time of Sofosbuvir and Velpatasvir were fo

APA, Harvard, Vancouver, ISO, and other styles

4

Nekkala, Kalpana, Shanmukha Kumar J V, Shanmukha Kumar J V, et al. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD." Asian Journal of Pharmaceutical and Clinical Research 11, no. 2 (2018): 164. http://dx.doi.org/10.22159/ajpcr.2018.v11i2.22465.

Full text

Abstract:

Objectives: The purpose of the research is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of sofosbuvir and velpatasvir drug product by rp-hplc methodMethods: New Analytical method was developed for the estimation of Velpatasvir and Sofosbuvir in drug product by liquid chromatography. The chromatographic separation was achieved on C18 column (Luna 18 150*4.6mm3.0um) at ambient temperature. The separation achieved employing a mobile phase consists of 0.1%v/v Formic acid in water: Methanol: Acetonitrile (35:40:25). The flow rate was 0.8m

APA, Harvard, Vancouver, ISO, and other styles

5

Bhatt, Jay. "Analytical method development and validation of related substances by rphplc of sofosbuvir and velpatasvir tablets." Journal of medical pharmaceutical and allied sciences 11, no. 4 (2022): 5201–13. http://dx.doi.org/10.55522/jmpas.v11i4.4051.

Full text

Abstract:

The developed method was a simple, accurate, precise, specific and robust method for the validation of Sofosbuvir and Velpatasvir Tablets by reverse phase high pressure liquid chromatography. For Sofosbuvir and Velpatasvir Tablets Chromatography was performed on Agilent 1200 series, UV and PDA Detector, Waters X-bridge C18 (150 mm x 4.6 mm, 3.5 µm) by using Mobile Phase A contains Buffer solution (0.6% Trifluroacetic acid in water adjusted pH to 2.2±0.05) : Acetonitrile (95:5)%v/v and Mobile Phase B contains mixture of purified water, methanol and acetonitrile in the ratio of (20: 30: 50) % v/

APA, Harvard, Vancouver, ISO, and other styles

6

Ahmed, Tanveer, Omer Hassaan Aftab Ahmad, Muhammad Bilal, Sher Alam, Shirjeel Zaheer, and Zaid Gul. "Comparison of Efficacy of Sofosbuvir & Daclatasvir with Sofosbuvir and Velpatasvir in Achieving SVR in Patients of Chronic Hepatitis C with Genotype 3." Pakistan Journal of Medical and Health Sciences 16, no. 4 (2022): 1155–58. http://dx.doi.org/10.53350/pjmhs221641155.

Full text

Abstract:

Background and Aim: Hepatitis C virus of chronic nature has been appreciated globally to be a major source of hepatic carcinomas and other abnormalities associated with liver function. The epidemiological data on the prevalence of the Hepatitis C virus shows a trend of 71 million people being affected by the disease globally with an annual mortality rate of 3.5 to 5 million death. Pakistan showed a prevalence of up to 8.2% which is among the most common incidents in countries. Since genotype 3 is the most common variant in Pakistan there remains a literature gap that evaluates the effectivenes

APA, Harvard, Vancouver, ISO, and other styles

7

Aya R Hussein, Halder J Abozait, and Nawfal R Hussein. "Successful Sofosbuvir/Velpatasvir retreatment in two pediatric oncology patients with chronic hepatitis C after initial DAA failure: A case report." World Journal of Advanced Research and Reviews 26, no. 2 (2025): 775–78. https://doi.org/10.30574/wjarr.2025.26.2.1733.

Full text

Abstract:

Hepatitis C virus (HCV) infection remains a significant concern for pediatric oncology patients who require multiple blood transfusions. Although direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, recurrence after initial treatment can occur. We report two pediatric oncology patients who experienced HCV relapse after standard DAA regimens but responded successfully to retreatment with sofosbuvir/velpatasvir. Patient 1, a 14-year-old with acute leukemia, was diagnosed with HCV genotype 1. Despite initial successful treatment with ledipasvir/sofosbuvir, HCV RNA reappeared

APA, Harvard, Vancouver, ISO, and other styles

8

Goher Ayub and Brig. Jamal Waris. "Efficacy of Velpatasvir Sofosbovir alone Versus in Combination with Ribavarin in Cirrhotic Patients with Hepatitis C." Indus Journal of Bioscience Research 3, no. 5 (2025): 49–54. https://doi.org/10.70749/ijbr.v3i5.1153.

Full text

Abstract:

Background: Chronic Hepatitis C (HCV) infection is a major cause of liver cirrhosis and its complications. Direct-acting antivirals (DAAs) such as sofosbuvir and velpatasvir have shown high efficacy in treating HCV, but the additional role of ribavirin in combination therapy remains uncertain, particularly in cirrhotic patients. Objective: This study compares the efficacy and safety of sofosbuvir/velpatasvir alone versus in combination with ribavirin in cirrhotic patients with HCV. Methods: This randomized controlled trial was conducted at the Department of Medicine, CMH Kharian. A total of 12

APA, Harvard, Vancouver, ISO, and other styles

9

Bhargavi, S., and B. Sailaja. "Development of Reverse Phase HPLC Method and Validation: Sofosbuvir and Velpatasvir Quantification in Bulk and Tablets." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 14, no. 04 (2023): 831–36. http://dx.doi.org/10.25258/ijpqa.14.4.01.

Full text

Abstract:

A new reverse-phase high-performance liquid chromatography (RP-HPLC) method for measuring the amount of sofosbuvir and velpatasvir in active pharmaceutical ingredients (API) and tablet forms has been developed and the method was also validated. Discovery column C18 150 mm x 4.6 mm, pore size of 5 μm was used for the analysis of drugs. Elution of drugs was achieved with 0.1% OPA Buffer: Acetonitrile mixed in the proportion of 40:60 v/v was used as mobile phase, maintaining 1.0 mL/min as flow rate, column temperature maintained at 30°C and uv detector wavelength was fixed at 272 nm. Sofosbuvir a

APA, Harvard, Vancouver, ISO, and other styles

10

Hsu, Po-Yao, Yu-Ju Wei, Jia-Jung Lee, et al. "Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis." Clinical and Molecular Hepatology 27, no. 1 (2021): 186–96. http://dx.doi.org/10.3350/cmh.2020.0180.

Full text

Abstract:

Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.Methods: The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.Results: Of 2,015 hemodialysis patients screened in 2019, 169 patients sero

APA, Harvard, Vancouver, ISO, and other styles

11

Nikhil Reddy C, Bala Krishna K, Narender Boggula, Sadhana Kanukuntla, Vasudha Bakshi, and Vivek Kumar Kunduru. "To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients." International Journal of Research in Pharmaceutical Sciences 11, SPL4 (2020): 972–79. http://dx.doi.org/10.26452/ijrps.v11ispl4.4231.

Full text

Abstract:

Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis viruses are the most common cause of hepatitis in the world, but other infections, toxic substances (e.g. alcohol, certain drugs), and auto-immune diseases can also cause hepatitis. To assess the treatment efficacy of sofosbuvir and velpatasvir to chronic hepatitis C virus-infected patients and to assess the treatment efficacy among the various subgroups of the treated patients. The primary endpoint will be to assess sustained virologic resp

APA, Harvard, Vancouver, ISO, and other styles

12

P., Seetharamaiah* Nagaraju Pappula JVLN. Seshagiri Rao and D. Gowrisankar. "Development And Validation of New RP-HPLC Method For the Simultaneous Estimation of Sofosbuvir And Velpatasvir In Combined Pharmaceutical Dosage Form." Int. J. in Pharm. Sci., 1, no. 7 (2023): 220–29. https://doi.org/10.5281/zenodo.8138641.

Full text

Abstract:

A simple, rapid, accurate, precise, specific and sensitive reverse phase-HPLC method has been developed and validated for the simultaneous estimation of Sofosbuvir and Velpatasvir in bulk and pharmaceutical dosage form. The chromatographic separation was performed on the Discovery C18 column (250mm×4.6mm, 5μm particle size), using a mobile phase of OPA (0.1%): Acetonitrile = 50:50 (v/v), at a flow rate of 1.0 ml/min in an ambient temperature of 25˚C with the detection wavelength of 260nm. The retention times of Sofosbuvir and Velpatasvir were 2.47 min and 3.32 min respectively. The li

APA, Harvard, Vancouver, ISO, and other styles

13

Onofrio, Fernanda Q., Curtis Cooper, Sergio M. Borgia, et al. "Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry." Clinical Infectious Diseases 72, no. 11 (2021): e799-e805. http://dx.doi.org/10.1093/cid/ciaa1510.

Full text

Abstract:

Abstract Background Despite the current highly effective therapies with direct-acting antiviral agents (DAAs), some patients with chronic hepatitis C virus (HCV) infection still do not achieve sustained virological response (SVR) and require retreatment. Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the first-line retreatment option for most patients. The aim of this study was to evaluate the efficacy of SVV as salvage therapy after at least one course of DAA. Methods Data were collected on all HCV-infected patients who failed DAAs and were prescribed SVV from a prospective Canad

APA, Harvard, Vancouver, ISO, and other styles

14

Hanuman, T., T. Sivakkumar, and S. Sridhar. "New Analytical Method Development and Validation for Simultaneous Estimation of Sofosbuvir and Velpatasvir in Bulk and Pharmaceutical Dosage Form by RP-HPLC Method." Journal of Drug Delivery and Therapeutics 10, no. 5 (2020): 143–48. http://dx.doi.org/10.22270/jddt.v10i5.4296.

Full text

Abstract:

A simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination Sofosbuvir and Velpatasvirin pharmaceutical dosage form. The column used was Kromosil C18(150mm x 4.6 mm, 5mm)in isocratic mode, with mobile phase containing phosphate buffer andacetonitrile(70:30v/v). The buffer is prepared by adding 1.41gm of sodium dihyrogen ortho phosphate in a 1000ml of volumetric flask add about 900ml of milli-Q water added and degas to sonicate and finally make up the volume with water then pH adjusted to 3.5 with dil. orthophosph

APA, Harvard, Vancouver, ISO, and other styles

15

Bashir, Muhammad Badar, Hafiz Bilal Bashir, and Mahpara Munir. "Efficacy of velpatasvir and sofosbuvir in treatment of chronic hepatitis C." Professional Medical Journal 28, no. 02 (2021): 153–57. http://dx.doi.org/10.29309/tpmj/2021.28.02.5535.

Full text

Abstract:

Objective: To determine the efficacy of sofosbuvir and velpatasvir in treatment of all genotypes of chronic HCV infection. Study Design: Descriptive Case study Setting: Department of Medicine Independent University Hospital Faisalabad. Period: December 2019 to May 2020. Material & Methods: Among patients of chronic hepatitis C presenting in the medical OPD of independent university hospital willing to participate, 80 were included in this study. They were given combination of sofosbuvir and velpatasvir 400/100 mg (FDC) once daily. They were monitored by serum ALT and PCR to HCV quantitativ

APA, Harvard, Vancouver, ISO, and other styles

16

Uppalapati.Jyothi*1, Dr.Parimi.Umadevi2. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY RP-HPLC METHOD." INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH 07, no. 09 (2017): 401–9. https://doi.org/10.5281/zenodo.1036448.

Full text

Abstract:

A novel reversed phase high performance liquid chromatography (RP-HPLC) method has been developed for the estimation of Sofosbuvir and Velpatasvir drug product by liquid chromatography. The chromatographic separation was achieved on C18 column (XTerra RP18 150*4.6, 5um) at ambient temperature .The separation achieved employing a mobile phase consists of 0.1%v/v Trifluoro acetic acid in water: Methanol (42:58). The flow rate was 1.0 ml/ minute and ultra violet detector at 269nm. The average retention time for Sofosbuvir and Velpatasvir found to be 3.44 and 4.68 min. The proposed method was vali

APA, Harvard, Vancouver, ISO, and other styles

17

Bernhard, Benedikt, and Felix Stickel. "Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report." Zeitschrift für Gastroenterologie 58, no. 05 (2020): 451–55. http://dx.doi.org/10.1055/a-1131-8058.

Full text

Abstract:

Abstract Background Relapses after therapy with direct-acting antiviral agents (DAA) in chronic hepatitis C virus (HCV) infections are rare due to high efficacy of interferon-free therapy regimens. The presence of resistance-associated substitutions (RAS) in proteins targeted by therapy can lead to lower rates of sustained virological response (SVR) in patients receiving DAA-therapy, and little evidence exists as to how to treat these patients. Case Summary We present a case of a multi-drug-resistant HCV-genotype-3a-infection in a 50-year-old female without confirmed cirrhosis but with advance

APA, Harvard, Vancouver, ISO, and other styles

18

Babur, Waseem, Naveed Noor Khan, Syed Meerab Javed, Zille Huma, Fayaz Ahmed Memon, and Abdul Azeem. "Combine treatment of Sofosbuvir and Velpatasvir in Patients of Chronic Hapatitis C." Pakistan Journal of Medical and Health Sciences 16, no. 5 (2022): 1086–89. http://dx.doi.org/10.53350/pjmhs221651086.

Full text

Abstract:

Objective: The purpose of this research is to evaluate how well individuals with chronic hepatitis C respond to a combination treatment consisting of sofosbuvir and velpatasvir. Study Design: Observational/ Prospective study Place of Study: King Salman Armed Forces Hospital Tabuk KSA and Dow University of Health Sciences Karachi Pakistan. Duration of Study: Jan, 2021 to Dec, 2021 Methods: This research included 42 participants of both sexes. Patients ranged in age from 20 to 78. After obtaining written permission, we collected demographic data about the patient, including age, gender, and heig

APA, Harvard, Vancouver, ISO, and other styles

19

Wali, Agha, Ghulam Hassan, Sohail Hussain, and Muhammad Naeem Aslam. "Effectiveness of Sofosbuvir and Velpatasvir Combination in Chronic Hapatitis C." Pakistan Journal of Medical and Health Sciences 16, no. 8 (2022): 790–92. http://dx.doi.org/10.53350/pjmhs22168790.

Full text

Abstract:

Objective: The purpose of this research is to evaluate the efficacy of a combination medication consisting of sofosbuvir and velpatasvir in treating individuals with chronic hepatitis C. Study Design: Observational/ Prospective study Place and Duration: Conducted at Department of Gastroenterology Mayo Hospital Lahore, during from the period Feb 2021 to Jan 2022. Methods: There were 67 participants in this study. The patients' ages ranged from 18 to 70. We gathered demographic information about the patient, such as age, gender, height, and weight, after getting written consent. Hepatitis C pati

APA, Harvard, Vancouver, ISO, and other styles

20

Bonaventura, Aldo, and Fabrizio Montecucco. "Sofosbuvir/velpatasvir: A promising combination." World Journal of Hepatology 8, no. 19 (2016): 785. http://dx.doi.org/10.4254/wjh.v8.i19.785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bandla, Jahnavi, and S. Ganapaty. "Stability indicating RP-HPLC method development and validation for the simultaneous determination of Sofosbuvir and Velpatasvir in tablet dosage forms." Indian Journal of Pharmaceutical and Biological Research 5, no. 04 (2017): 10–16. http://dx.doi.org/10.30750/ijpbr.5.4.3.

Full text

Abstract:

Stability indicating RP-HPLC method was developed for the simultaneous quantitation of Sofosbuvir and Velpatasvir in its pharmaceutical dosage form and validated. The drugs were separated on Discovery C18 (150mm x 4.6mm, 5μ) column using 0.01N potassium dihydrogen phosphate buffer and acetonitrile (50:50%v/v) as mobile phase on isocratic mode. The mobile phase is pump into the column at flow rate of 1.0ml/min and column oven temperature is maintained at 30ºC. The drugs were detected at a wavelength 240nm. The retention time for Sofosbuvir and Velpatasvir were found to be 2.32min and 3.34min re

APA, Harvard, Vancouver, ISO, and other styles

22

Hikita, Hayato, and Tetsuo Takehara. "NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors." Seminars in Liver Disease 40, no. 02 (2019): 143–53. http://dx.doi.org/10.1055/s-0039-3402001.

Full text

Abstract:

AbstractNS5A-P32 deletion (P32del) is a resistance-associated amino acid change that has recently gained popularity in direct-acting antiviral treatment for chronic hepatitis C. Although not yet detected in naive patients, it appears in 5 to 10% of hepatitis C genotype 1b patients who fail to respond to daclatasvir/asunaprevir and sofosbuvir/ledipasvir treatments. In contrast to signature resistance-associated substitutions, such as substitutions at the NS5A-L31 and NS5A-Y93 positions, it shows complete resistance to all NS5A inhibitors in replicon and cell culture. Studies of humanized liver

APA, Harvard, Vancouver, ISO, and other styles

23

Pramod, G. R., S. Vishwamitra Kishan, T. N. Kamalesh, and G. Yeshavanth. "Case Series of Responders to Sofosbuvir Plus Velpatasvir Based Combination Therapy for Hepatitis C in Chronic Kidney Disease Who are on Maintenance Hemodialysis." International Journal of Pharmaceutical and Clinical Research 15, no. 8 (2023): 27–29. https://doi.org/10.5281/zenodo.11448039.

Full text

Abstract:

Hepatitis C Virus (HCV) infection is a major infection worldwide, with 12.5 million people infected in India alone. In hemodialysis undergoing CKD population in specific, the prevalence of HCV is 4.3 – 45 %. It leads to accelerating decline of renal and liver functions causing higher mortality in hemodialysis patients. WHO recommends use of pan-genotypic, direct-acting anti-virals for the treatment of HCV. Sofosbuvir, in combination with other antivirals, led to a significant paradigm change in the treatment of HCV. Sofosbuvir is metabolized in the liver into an active metabolite which i

APA, Harvard, Vancouver, ISO, and other styles

24

Khan, R. A., A. Ali, S. Munib, I. Muhammad, NOSHER WAN, and Amjad Ali. "Effectiveness of Sofosbuvir and Velpatasvir Combination in Chronic Hepatitis C with Hemodialysis Patients." Pakistan Journal of Medical and Health Sciences 15, no. 5 (2021): 1205–7. http://dx.doi.org/10.53350/pjmhs211551205.

Full text

Abstract:

Objective: The aim of this study is to determine the response of sofosbuvir and velpatasvir combination in chronic hepatitis C with hemodialysis patients. Study Design: Prospective/observational study Place and Duration: The study was conducted at department of Nephrology Nawaz Sharif Kidney Hospital, Swat for duration of six months from 1st July to 31st December, 2020. Methods: Total 27 patients of both genders were presented in this study. Patients were aged between 18-85 years. Patients details demographics age, sex and body mass index were recorded after taking written consent. Patients di

APA, Harvard, Vancouver, ISO, and other styles

25

Lichert, Frank. "HCV: Sofosbuvir, Velpatasvir plus GS-9857." Zeitschrift für Gastroenterologie 55, no. 01 (2017): 1–2. http://dx.doi.org/10.1055/s-0042-116999.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hussar, Daniel A., and William P. Tidwell. "Elbasvir/grazoprevir, Velpatasvir/sofosbuvir, and Eteplirsen." Journal of the American Pharmacists Association 57, no. 1 (2017): 129–32. http://dx.doi.org/10.1016/j.japh.2016.11.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

"Sofosbuvir/velpatasvir/Sofosbuvir/velpatasvir/voxilaprevir." Reactions Weekly 1968, no. 1 (2023): 281. http://dx.doi.org/10.1007/s40278-023-44445-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir." Reactions Weekly 2066, no. 1 (2025): 383. https://doi.org/10.1007/s40278-025-85389-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Ribavirin/sofosbuvir/sofosbuvir/velpatasvir." Reactions Weekly 1871, no. 1 (2021): 367. http://dx.doi.org/10.1007/s40278-021-01886-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Sofosbuvir/velpatasvir." Reactions Weekly 1853, no. 1 (2021): 435. http://dx.doi.org/10.1007/s40278-021-95301-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Sofosbuvir/velpatasvir." Reactions Weekly 1837, no. 1 (2021): 647. http://dx.doi.org/10.1007/s40278-021-89246-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Sofosbuvir/velpatasvir." Reactions Weekly 1856, no. 1 (2021): 364. http://dx.doi.org/10.1007/s40278-021-96357-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Sofosbuvir/velpatasvir." Reactions Weekly 1841, no. 1 (2021): 218. http://dx.doi.org/10.1007/s40278-021-90720-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Sofosbuvir/velpatasvir." Reactions Weekly 1848, no. 1 (2021): 354. http://dx.doi.org/10.1007/s40278-021-93356-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Sofosbuvir/velpatasvir." Reactions Weekly 1912, no. 1 (2022): 408. http://dx.doi.org/10.1007/s40278-022-18111-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Sofosbuvir/velpatasvir." Reactions Weekly 1916, no. 1 (2022): 386. http://dx.doi.org/10.1007/s40278-022-19845-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Sofosbuvir/velpatasvir." Reactions Weekly 1921, no. 1 (2022): 258. http://dx.doi.org/10.1007/s40278-022-22252-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Sofosbuvir/velpatasvir." Reactions Weekly 1922, no. 1 (2022): 532. http://dx.doi.org/10.1007/s40278-022-22817-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Sofosbuvir/velpatasvir." Reactions Weekly 1922, no. 1 (2022): 533. http://dx.doi.org/10.1007/s40278-022-22818-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Sofosbuvir/velpatasvir." Reactions Weekly 1904, no. 1 (2022): 414. http://dx.doi.org/10.1007/s40278-022-14346-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Sofosbuvir/velpatasvir." Reactions Weekly 1872, no. 1 (2021): 453. http://dx.doi.org/10.1007/s40278-021-02379-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Sofosbuvir/velpatasvir." Reactions Weekly 1893, no. 1 (2022): 302. http://dx.doi.org/10.1007/s40278-022-10085-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Sofosbuvir/velpatasvir." Reactions Weekly 1871, no. 1 (2021): 378. http://dx.doi.org/10.1007/s40278-021-01897-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Sofosbuvir/velpatasvir." Reactions Weekly 1896, no. 1 (2022): 419. http://dx.doi.org/10.1007/s40278-022-11207-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Sofosbuvir/velpatasvir." Reactions Weekly 1896, no. 1 (2022): 418. http://dx.doi.org/10.1007/s40278-022-11206-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Sofosbuvir/velpatasvir." Reactions Weekly 2020, no. 1 (2024): 410. http://dx.doi.org/10.1007/s40278-024-64775-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Sofosbuvir/velpatasvir." Reactions Weekly 2043, no. 1 (2025): 360. https://doi.org/10.1007/s40278-025-75641-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Sofosbuvir/velpatasvir." Reactions Weekly 1837, no. 1 (2021): 647. http://dx.doi.org/10.1007/s40278-021-89246-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Sofosbuvir/velpatasvir." Reactions Weekly 1795, no. 1 (2020): 251. http://dx.doi.org/10.1007/s40278-020-76272-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Sofosbuvir/velpatasvir." Reactions Weekly 1941, no. 1 (2023): 327. http://dx.doi.org/10.1007/s40278-023-32589-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!